AM Press ReleasesBioprinting

Rousselot Biomedical launches Quali-Pure HGP 2000

Pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications

Stay up to date with everything that is happening in the wonderful world of AM via our LinkedIn community.

Rousselot, Darling Ingredients’ health brand and the global leader of collagen-based solutions1, launched Quali-Pure HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications. As the latest addition to Rousselot Biomedical’s rapidly expanding product offering, this new non-gelling hydrolyzed gelatin further extends the scope of biomedical applications covered by Rousselot products.

Quali-Pure HGP 2000 for vaccines and wound healing

Gelatin, in its non-gelling hydrolyzed form, has long been used as a protein or peptide excipient in vaccine formulations due to its natural biocompatibility and biodegradability and its ability to stabilize vaccines. When used in wound healing, gelatin has been shown to stimulate the migration of cells, particularly fibroblasts, to the wound site and to promote the formation of new tissue.

Quali-Pure HGP 2000 not only has the optimal functionalities for these biomedical applications, but it also comes with the additional benefits of controlled endotoxin levels and enhanced regulatory compliance, setting it apart from similar products on the market.

Expanding the Quali-Pure range

The new Quali-Pure HGP 2000 is part of the recently launched Quali-Pure range. All products within this range offer controlled endotoxin levels and batch-to-batch consistency. They meet stringent quality and safety standards and offer full and documented traceability up to the farm (ISO 22442-2), validated viral inactivation (ISO 22442-3) and IPEC GMP compliance. They also support the new EU Medical Device Regulation (MDR) 2017/745 which must be fully implemented by May 2024.

According to Kathleen Jacobs, Global Regulatory Affairs Director at Rousselot Biomedical, “We are very proud to bring this new product to the market. With Quali-Pure HGP 2000, pharmaceutical manufacturers are not only choosing quality, safety and consistency, but they can also achieve peace of mind knowing that all our Biomedical gelatins are compliant with the more stringent regulations coming in force.”

1. Global Gelatin Market Insights Forecast to 2026 Calibre Research, 2020


Composites AM 2024

746 composites AM companies individually surveyed and studied. Core composites AM market generated over $785 million in 2023. Market expected to grow to $7.8 billion by 2033 at 25.8% CAGR. This new...


VoxelMatters is the online trade media portal published by 3dpbm, a leading marketing and market research firm specializing in the AM industry. 3dpbm also publishes the 3D Printing Business Directory, the AM Focus eBook series and the 3dpbm Research AM Market Reports. 3D Printing Media Network was founded with the goal to provide the latest industry news, insights and opinions to a global audience of professionals and decision makers.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button
Close Popup
Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

Technical Cookies
In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services


Join our 12,000+ Professional community and get weekly AM industry insights straight to your inbox. Our editor-curated newsletter equips executives, engineers, and end-users with crucial updates, helping you stay ahead.